Discovery Engine

Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA for chronic weight management in adults and adolescents with obesity...

Zepbound (tirzepatide) is a novel, once-weekly injectable dual agonist that activates GIP and GLP-1 receptors, providing synergistic effects on appeti...

Saxenda (liraglutide) is a once-daily GLP-1 receptor agonist originally developed for type 2 diabetes but later approved for chronic weight management...

Rybelsus is the first oral formulation of semaglutide, FDA-approved for type 2 diabetes management. While not officially indicated for weight loss, it...

Qsymia is a once-daily oral combination of phentermine (a sympathomimetic appetite suppressant) and topiramate ER (an anticonvulsant with weight loss...

Contrave (naltrexone/bupropion) is an oral, centrally acting combination medication approved for chronic weight management in adults with obesity or o...

Ozempic (semaglutide) is a once-weekly injectable medication from Novo Nordisk, FDA-approved for type 2 diabetes management. By mimicking the GLP-1 ho...

Mounjaro (tirzepatide) is an FDA-approved injectable medication developed by Eli Lilly, originally indicated for type 2 diabetes management. As a dual...

A behavior-change app combining psychology and coaching to foster sustainable weight loss and healthier habits through personalized lessons, goal-sett...

A clinician-led, telehealth metabolic health program focused on reversal of type 2 diabetes and sustainable weight loss through keto-style nutrition c...